The TRUPCR® Acute Leukemia Panel Kit is intended for the qualitative detection & differentiation of 18 diagnostic and prognostic markers of Acute Myelogenous Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in peripheral blood samples using real-time PCR.
The TRUPCR® ALL PCR panel is intended for the qualitative detection of diagnostic and prognostic markers of acute lymphoblastic leukemia (ALL) in peripheral blood samples using real time PCR system.
TRUPCR® AML Panel Kit is intended for the qualitative detection & differentiation of diagnostic and prognostic markers of Acute Myelogenous Leukemia in peripheral blood or bone marrow samples using real-time and conventional PCR system.
The TRUPCR® FUSION GENE Panel is intended for the qualitative detection of diagnostic and prognostic markers of leukemia (FUSION GENE) in peripheral blood samples using real time PCR system.
The TRUPCR® MPN Panel Kit is intended for the qualitative detection of JAK2-V617F, CALR, MPL W515K/L mutations and BCR-ABL1 translocation in Myeloproliferative neoplasms (MPNs) in peripheral blood samples using real time PCR system.
The TRUPCR ® Paediatric Leukemia Panel Kit is intended for the qualitative detection of 18 markers of paediatric leukemia in peripheral blood samples using Real-Time PCR system. TRUPCR® Paediatric Leukemia Panel Kit requires cDNA as template. RNA should be extracted from the samples and then it should be converted to cDNA using components provided in kit
The TRUPCR® C-KIT Mutation Detection is a PCR-based in vitro diagnostic test designed to detect D816V in the C-KIT gene in genomic DNA extracted from peripheral blood of patients diagnosed with acute myelogenous leukemia (AML) or other malignancy.
The TRUPCR® CALR Kit is qualitative assay for the detection of CALR mutations in genomic DNA from whole blood of subjects suspected of myeloproliferative neoplasms (MPN).
The TRUPCR®CXCR4 Mutations Detection Kit is an in vitro diagnostic test intended for the qualitative detection of S338X mutation (c.1013C>G and c.1013C>A, NM_003467.3) in C-X-C motif chemokine receptor 4 (CXCR4) gene from human genomic DNA, extracted from whole blood/bone marrow/FFPE tissue.
Fluoropyrimidines such as 5-flurouracil (5-FU), capecitabine and tegafur are commonly used drugs for treating solid tumors. These drugs are metabolized in the liver by enzyme dihydropyrimidine dehydrogenase (DPD) which inactivates more than 80% of these drugs.
The TRUPCR® FLT3 Mutation Detection is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutation (D835-I836) in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood of patients diagnosed with acute myelogenous leukemia (AML).
TRUPCR® JAK2 Kit (V2.0) is a real-time polymerase chain reaction (PCR) assay for qualitative detection of V617F mutation in JAK2 (Janus Kinase 2) gene against a background of wild-type genomic DNA.
TRUPCR JAK-2 allele burden kit is a real-time polymerase chain reaction (PCR) assay for quantification V617F mutation in JAK-2 (Janus Kinase 2) gene against a background of wild-type genomic DNA.
The TRUPCR® MYD88 Mutation Detection Kit is an in vitro diagnostic test intended for the qualitativedetection of L265P mutation in c.
TRUPCR® NPM1 Mutation Quantitative Kit is an in-vitro nucleic acid amplification assay for the qualitative detection and quantification of NPM1 mutant allelic burden in clinical samples.
The Nucleophosmin (NPM1) gene is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in about 35% of AML patients at diagnosis and in approximately 60% of adult cytogenetically normal AML (CN-AML).
Detection of the PML-RARA t(15;17) translocation is diagnostic for acute promyelocytic leukemia (APL), although the diagnosis can also be based on morphology.
TRUPCR® PML-RARA is an in-vitro nucleic acid amplification assay for the qualitative and quantitative detection of PML/RAR-alpha fusion transcriptsin human clinical samples.
Chronic myeloid leukemia (CML) is characterized by the consistent involvement of the Philadelphia chromosome (Ph) and the BCR-ABL fusion gene, which derives from the reciprocal translocation t(9;22)(q34;q11) between chromosome 9 and 22
The BCR-ABL1 Detection Kit is intended for the qualitative detection of BCR-ABL1 fusion gene (Major-BCR, minor-BCR, and micro -BCR) in bone marrow or peripheral blood samples using real time PCR system.
TRUPCR® BCR-ABL QT kit is a RT-qPCR test for the quantitative detection of BCR-ABL fusion transcripts in bone marrow or peripheral blood samples.
TRUPCR® BCR-ABL1 Transcript Screening Kit is a RT-qPCR test for the detection and differentiation of BCR-ABL fusion transcripts in bone marrow or peripheral blood samples.
The TRUPCR® BRAF Mutation Kit is an in vitro diagnostic test intended for the qualitative detection of BRAF somatic mutations in the genomic DNA extracted from fresh, frozen or formalin fixed paraffin-embedded (FFPE) tissue.
The TRUPCR® EGFR Kit is an in vitro diagnostic test intended for the qualitative detection of EGFR somatic mutations in the genomic DNA extracted from fresh, frozen or formalin fixed paraffin-embedded (FFPE) tissue or liquid biopsy.
The TRUPCR® KRAS PCR Kit (K-RAS Kit) is an in vitro diagnostic test intended for the qualitative detection of KRAS somatic mutations in the genomic DNA extracted from fresh, frozen or formalin fixed paraffin-embedded (FFPE) tissue.
The TRUPCR® MGMT Methylation Detection Kit is specifically designed to assess the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. This crucial biomarker plays a pivotal role in predicting the response of glioblastoma patients to alkylating agents like temozolomide (TMZ).
The TRUPCR® NRAS Mutation Kit is an in vitro diagnostic test intended for the qualitative detection of NRAS somatic mutations in the genomic DNA extracted from fresh, frozen or formalin fixed paraffin-embedded (FFPE) tissue.
The TRUPCR® ROS1 Gene Fusions Detection Kit is intended for the qualitative detection of 14 ROS1 gene fusions in human NSCLC formalin-fixed paraffin- embedded (FFPE) tissue samples using real time PCR system.
3B BlackBio Biotech India Limited is now 3B BlackBio Dx Limited as a result of amalgamation with it's parent company Kilpest India Limited. 3B BlackBio Dx is a leading Indian company in the field of PCR based Molecular Diagnostic Kits. We offer technical support and training on all our products and are committed to increasing the efficiency of laboratory testing and enhancing patient care.
The Company is ISO 13485:2016 certified, GMP compliant biotech R&D organization.
General enquires: info@3bblackbio.com
Corporate Enquiry:
+91 9691680693,+91 9810562700
Orders: info@3bblackbio.com
Tel: 0755 - 4076518, 4077847
